Patients with progressive kidney disease may experience the same medicinal benefits of consuming caffeinated drinks as the general population, according to data recently presented at Kidney Week 2017.

“We assessed the extent to which CKD stage modified the effects of caffeine consumption on mortality with likelihood ratio tests for interaction,” Miguel Bigotte Vieira, MD, of the Centro Hospitalar in Lisboa, Portugal, and colleagues wrote in the abstract.

Researchers reviewed data from 2,328 patients with CKD, which was defined as GFR less than 60 mL/min/1.73 m2, who were part of the National Health and Nutrition Examination Survey from 1999 to 2010 to determine a mortality benefit among patients who consumed caffeine. The researchers established a baseline of caffeine use by using 24-hour dietary recalls. The researchers used Cox proportional hazard models to estimate hazard ratios for all-cause mortality, based on caffeine consumption. They adjusted the model for gender, age, race and annual family income. The researchers also studied education level, estimated GFR, albumin/creatinine ratio, hypertension, smoking status, dyslipidemia, BMI, diet and previous cardiovascular events.

Patients were placed in different quartiles based on their caffeine consumption: 1st quartile (less than 29.5 mg of caffeine/day); 2nd quartile (30.5 to 101 mg/day); 3rd quartile (101.5 to 206 mg/day); and 4th quartile (206.5 to 1378.5 mg/day).

Researchers found a dose-dependent inverse association between caffeine and all-cause mortality after adjusting for confounders, the researchers reported.

“There were no significant interactions between caffeine consumption quartiles and CKD stages with respect to all-cause mortality,” the researchers wrote.

Reference:
Bigotte Vieira M, et al. Abstract FR-PO516. Presented at: Kidney Week 2017; Oct. 31-Nov. 5, 2017; New Orleans.

Disclosure: The authors report no relevant financial disclosures.